Activation of NFkB is a novel mechanism of pro-survival activity of glucocorticoids in breast cancer cells

Cancer Letters

Volumn 337, Issue 1, 2013, Pages 90-95

  Khan, Shagufta ^a   Lopez Dee, Zenaida ^a   Kumar, Raj ^a   Ling, Jun ^a  

^a PA Professor of Surgery Department of Clinical Sciences The Geisinger Commonwealth Medical College Scranton   (United States)

Author keywords

Breast cancer; C Myc; Glucocorticoid receptor (GR); NFkB

Indexed keywords

EID: 84880038274     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.05.020     Document Type: Article

References (37)

1. Sorlie T., Tibshirani R., Parker J., Hastie T., Marron J.S., Nobel A., et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl. Acad. Sci. USA 2003, 100:8418-8423.
2. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., et al. The genomic and transcriptomic architecture of 2000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352.
3. Conzen S.D. Nuclear receptors and breast cancer. Mol. Endocrinol. 2008, 22:2215-2228.
4. Vogel V.G., Costantino J.P., Wickerham D.L., Cronin W.M., Cecchini R.S., Atkins J.N., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 2006, 95:2727-2741.
5. Ghosh R., Narasanna A., Wang S.E., Liu S., Chakrabarty A., Balko J.M., et al. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res. 2011, 71:1871-1882.
6. Pal S.K., Childs B.H., Pegram M. Triple negative breast cancer: unmet medical needs. Breast Cancer Res. Treat. 2011, 125:627-636.
7. Horwitz K.B., Zava D.T., Thilagar A.K., Jensen E.M., McGuire W.L. Steroid receptor analyses of nine human breast cancer cell lines. Cancer Res. 1978, 38:2434-2437.
8. Horwitz K.B., Costlow M.E., McGuire W.L. MCF-7; a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors. Steroids 1975, 26:785-795.
9. Thompson E.B., Webb M.S., Miller A.L., Fofanov Y., Johnson B.H. Identification of genes leading to glucocorticoid-induced leukemic cell death. Lipids 2004, 39:821-825.
10. Greenstein S., Ghias K., Krett N.L., Rosen S.T. Mechanisms of Glucocorticoid mediated Apoptosis in Hematological Malignancies. Clin. Cancer Res. 2002, 8:1681-1694.
11. Rutz H.P. Effects of corticosteroid use on treatment of solid tumours. Lancet 2002, 360:1969-1970.
12. Keith B.D. Systematic review of the clinical effect of glucocorticoids on nonhematologic malignancy. BMC Cancer 2008, 28. 8:84.
13. Cocconi G., Bisagni G., Ceci G., Bacchi M., Boni C., Brugia M., et al. Low-dose aminoglutethimide with and without hydrocortisone replacement as a first-line endocrine treatment in advanced breast cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research. J. Clin. Oncol. 1992, 10:984-989.
14. Ingle J.N., Mailliard J.A., Schaid D.J., Krook J.E., Gesme D.H., Windschitl H.E., et al. A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer. A collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Cancer 1991, 68:34-39.
15. Sahoo S., Brickley D.R., Kocherginsky M., Conzen S.D. Coordinate expression of the PI3-kinase downstream effectors serum and glucocorticoid-induced kinase (SGK-1) and Akt-1 in human breast cancer. Eur. J. Cancer 2005, 41:2754-2759.
16. Wu W., Pew T., Zou M., Pang D., Conzen S.D. Glucocorticoid receptor-induced MAPK phosphatase-1 (MPK-1) expression inhibits paclitaxel-associated MAPK activation and contributes to breast cancer cell survival. J. Biol. Chem. 2005, 280:4117-4124.
17. Wu W., Chaudhuri S., Brickley D.R., Pang D., Karrison T., Conzen S.D. Microarray analysis reveals glucocorticoid-regulated survival genes that are associated with inhibition of apoptosis in breast epithelial cells. Cancer Res. 2004, 64:1757-1764.
18. Siegel P.M., Muller W.J. Transcription factor regulatory networks in mammary epithelial development and tumorigenesis. Oncogene 2010, 29:2753-2759.
19. I.M. Beck, W.V. Berghe, L. Vermeulen, K.R.Yamamoto, G. Haegeman, K.D. Bosscher, Crosstalk in inflammation: the interplay of glucocorticoid receptor based mechanisms and kinases and phosphatases, Endocr. Rev. 30 (2009) 830-882.
20. Ramdas J., Harmon J.M. Glucocorticoid-induced apoptosis and regulation of NF-kappaB activity in human leukemic T cells. Endocrinology 1998, 139:3813-3821.
21. Garside H., Stevens A., Farrow S., Normand C., Houle B., Berry A., et al. Glucocorticoid ligands specify different interactions with NF-kappaB by allosteric effects on the glucocorticoid receptor DNA binding domain. J. Biol. Chem. 2004, 279:50050-50059.
22. Cao Y., Karin M. NF-kappaB in mammary gland development and breast cancer. J. Mammary Gland Biol. Neoplasia 2003, 8:215-223.
23. Baud V., Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 2009, 8:33-40.
24. Hynes N.E., Stoelzle T. Key signaling nodes in mammary gland development and cancer: Myc. Breast Cancer Res. 2009, 11:210.
25. Mitchell T., Sugden B. Stimulation of NF-kappa B-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J. Virol. 1995, 69:2968-2976.
26. Liden J., Delaunay F., Rafter I., Gustafsson J., Okret S. A new function for the C-terminal zinc finger of the glucocorticoid receptor. Repression of RelA transactivation. J. Biol. Chem. 1997, 272:21467-21472.
27. De Bosscher K., Vanden Berghe W., Vermeulen L., Plaisance S., Boone E., Haegeman G. Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell. Proc. Natl. Acad. Sci. USA 2000, 97:3919-3924.
28. Thulasi R., Harbour D.V., Thompson E.B. Suppression of c-myc is a critical step in glucocorticoid-induced human leukemic cell lysis. J. Biol. Chem. 1993, 268:18306-18312.
29. Ausserlechner M.J., Obexer P., Bock G., Geley S., Kofler R. Cyclin D3 and c-MYC control glucocorticoid-induced cell cycle arrest but not apoptosis in lymphoblastic leukemia cells. Cell Death Differ. 2004, 11:165-174.
30. Spriggs K.A., Cobbold L.C., Jopling C.L., Cooper R.E., Wilson L.A., Stoneley M., et al. Canonical initiation factor requirements of the Myc family of internal ribosome entry segments. Mol. Cell. Biol. 2009, 29:1565-1574.
31. Chen Y., Olopade O.I. MYC in breast tumor progression. Expert Rev. Anticancer Ther. 2008, 8:1689-1698.
32. Pratt M.A., Tibbo E., Robertson S.J., Jansson D., Hurst K., Perez-Iratxeta C., et al. The canonical NF-kappaB pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population. Oncogene 2009, 28:2710-2722.
33. Cancer Genome.Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
34. Lehmann B.D., Bauer J.A., Chen X., Sanders M.E., Chakravarthy A.B., Shyr Y., et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 2011, 121:2750-2767.
35. Hrushesky W.J., Lannin D., Haus E. Evidence for an ontogenetic basis for circadian coordination of cancer cell proliferation. J. Natl. Cancer Inst. 1998, 90:1480-1484.
36. Bower J.E., Ganz P.A., Irwin M.R., Arevalo J.M., Cole S.W. Fatigue and gene expression in human leukocytes: increased NF-κB and decreased glucocorticoid signaling in breast cancer survivors with persistent fatigue. Brain Behav. Immun. 2011, 25:147-150.
37. Antoni M.H., Lutgendorf S.K., Cole S.W., Dhabhar F.S., Sephton S.E., McDonald P.G., et al. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat. Rev. Cancer 2006, 6:240-248.